Approved FDA Indication Off-Label Use Risks
FDA · TGA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

Tesamorelin Dosage: Egrifta Label vs Off-Label Anti-Aging Use

Tesamorelin is FDA-approved as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA label specifies a daily subcutaneous injection dose for that indication. Off-label use for anti-aging or body composition in healthy adults is not characterised by FDA-supported safety data.

Tesamorelin is FDA-approved as Egrifta only for HIV-associated abdominal lipodystrophy. The FDA label specifies a daily subcutaneous dose for that indication. Off-label use for anti-aging or general body composition is not regulator-validated and is not characterised by adequately controlled human trials in healthy adults.

Key Takeaways

  • Tesamorelin (Egrifta) is FDA-approved only for HIV-associated abdominal lipodystrophy.
  • The label specifies daily subcutaneous injection dosing under specialist supervision.
  • Off-label anti-aging or body-composition use is not regulator-validated.
  • Labelled warnings include hypersensitivity, fluid retention, glucose intolerance, contraindication in active malignancy.
  • Allmeds does not publish off-label protocols.

Approved Egrifta dosing context

Egrifta is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA label specifies a daily subcutaneous injection dose used under specialist supervision. Allmeds does not republish self-administration protocols. Patients prescribed Egrifta should follow their prescribing information and clinician guidance.

Label warnings and contraindications

  • Hypersensitivity reactions.
  • Fluid retention, peripheral oedema, joint pain.
  • Glucose intolerance and new-onset diabetes.
  • Contraindicated in active malignancy, hypothalamic-pituitary axis disruption, and pregnancy.
  • Increased IGF-1 levels; monitoring recommended.

Off-label anti-aging use

Tesamorelin is marketed off-label for anti-aging and body composition. These uses are not FDA-approved. The off-label population (healthy adults) has not been characterised by adequately controlled human trials of efficacy or safety for those indications. Stimulating the GH/IGF-1 axis in healthy adults carries the same labelled risks (fluid retention, glucose intolerance, joint pain) and a theoretical malignancy concern.

Check your medications before any change

Allmeds scans interactions across your full list. Free for individuals; team plans available.

Try it free → Talk to Sales

Common Questions

What is the approved Egrifta dose?

The FDA label specifies a daily subcutaneous dose for HIV-associated lipodystrophy. Allmeds does not republish self-administration protocols. Patients should follow their prescribing information.

Can I use tesamorelin for anti-aging?

Anti-aging is not an FDA-approved use of tesamorelin. Off-label use is not regulator-validated and has not been characterised by adequately controlled human trials in that population.

Are there specific contraindications?

Yes. Per the FDA label, tesamorelin is contraindicated in active malignancy, disrupted hypothalamic-pituitary axis, and pregnancy. Hypersensitivity reactions are also a labelled risk.

Is compounded tesamorelin the same as Egrifta?

Compounded tesamorelin sold outside the Egrifta product is not pharmaceutical-grade in the same sense. Purity and potency are not guaranteed.

References

  1. U.S. Food & Drug Administration. Egrifta (tesamorelin) prescribing information. Source.
  2. Falutz J et al. Effects of tesamorelin on visceral fat. N Engl J Med. 2007;357:2359-2370. Source.
  3. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.